alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,876–1,900 of 1,906 studies in Treatments (page 76 of 77) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

What “Treatments” covers

Treatments — Drug and non-drug treatment research — what was tested, in whom, and what changed — plus the approvals and coverage decisions that followed.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

A Biophysical Framework for Neurodegeneration: Prioritizing Protein Homeostasis Over Aggregate Toxicity

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2025-12-31

Neurodegenerative research has long hypothesized that aggregated proteins such as amyloid‑β (Aβ), tau, and α‑synuclein (αSyn) are intrinsically toxic and are directly associated with the etiologies of Alzheimer’s disease (AD) and Parkinson’s disease (PD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

ScFv-h3D6 Prevents Bapineuzumab-Induced Hemorrhagic Events in the APP23 Mouse Model of Alzheimer’s Disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2025-11-05

The occurrence of amyloid-related imaging abnormalities (ARIA), found in clinical trials for Aβ-immunotherapy, has been related to the antibody’s effector function on glial activation by the Fc portion of the antibody. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-10-02

Our study examined the safety and tolerability of centralized lecanemab administration across a widely distributed region and suggests that use of distributed infusion sites increases access to disease-modifying treatment without significant increase in risk. 2 key findings →

Participants: 70 Evidence: low

Full summary, score breakdown and related studies → Original source

XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-09-27

The complete absence of ARIA distinguishes XPro1595 from amyloid-targeting therapies and supports its potential for use in combination strategies and potentially for those at a higher risk of ARIA. 5 key findings →

Design: clinical trial Evidence: high

Full summary, score breakdown and related studies → Original source

Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-20

Alzheimer's disease continues to be one of the major critical neurodegenerative ailments of the modern era, with acetylcholinesterase (AChE) inhibition standing as a foundational therapeutic strategy. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Substituent Effects on Electronic Properties and Acetylcholinesterase Inhibitory Potential of Donepezil Analogues: A DFT, Molecular Docking, and ADMET Study with Dynamics Validation of the Lead Candidate

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-05

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is the leading cause of dementia in older people. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Docking-Guided Design and Biological Evaluation of a Lead Convolvine-Based Acetylcholinesterase Inhibitor for Alzheimer's Disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-01

Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by cognitive decline, memory loss, and cholinergic dysfunction [1]. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

In silico design and physicochemical characterisation of a dual-action intranasal nanoparticle formulation for Alzheimer’s disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-28

Approved Alzheimer’s disease therapies fail to address the two drivers of cognitive decline: loss of BDNF-TrkB signalling and accumulation of hyperphosphorylated tau protein. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Synergistic Nano-Architectures: How Date Seed Phytochemicals and Cellulose Matrices Template Silver Nanoparticles for Multifunctional Therapy

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-07

This study reports the eco-friendly green synthesis of a multifunctional silver nanocomposite (DS-MC-Ag-nanocomposite) utilizing ethanolic extract of waste date seeds ( Phoenix dactylifera ) and methyl cellulose (MC) as dual reducing and stabilizing agents. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Early Amyloid-β Toxicity Disrupts Nervous System Connectivity During Aging in Caenorhabditis elegans

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-07-29

Our experiments revealed that nAβ expressing animals exhibit a unique loss of positively correlated neuron connectivity, premature disruption of system wide dynamics, and reduced overall neuronal activity. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Computational Screening of FDA-Approved Drugs as Potential BACE1 Inhibitors for Alzheimer's Disease Drug Repurposing

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-27

Alzheimer's disease is a progressive neurodegenerative disorder affecting over 55 million people worldwide, with no disease-modifying treatments currently approved. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Phenolic chemotypic diversity in Tunisian Hertia cheirifolia populations: influence of plant organs and phenological stages on antioxidant and anti-acetylcholinesterase activities

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-07

H. cheirifolia phenolic extracts exhibit potent, mechanism-specific antioxidant activity and promising AChE inhibition, validating traditional use in neurological complaints. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Treatment Effects of Cholinesterase Inhibitors in Alzheimer’s Disease: a Causal Machine Learning Approach

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-02-12

A bstract INTRODUCTION Treatment response in Alzheimer’s disease (AD) varies substantially across patients, yet no validated frameworks exist to estimate heterogeneous treatment effects (HTE) from observational data while controlling for confounding bias. 2 key findings →

Participants: 4,049 Evidence: low

Full summary, score breakdown and related studies → Original source

Real-World Performance of Urine β-amyloid Test Kits in Multiple Hospital Clinics and Neighborhood Communities of China

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-05-15

Our findings confirm the diagnostic value of urinary β-amyloid protein detection in MCI and AD-related dementia. 5 key findings →

Design: case-control study Participants: 51,187 Evidence: high

Full summary, score breakdown and related studies → Original source

Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer's amyloidosis

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Alzheimer's research & therapy 2021-02-08

Overall, these findings indicate that use of SLCP exerts neuroprotective properties by decreasing amyloid plaque burden, preventing neuronal death, and preserving dendritic spine density and synaptic markers in the 5xFAD mice. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2024-07-26

Although the first generation of immunotherapies for Alzheimer’s disease (AD) are now clinically approved, amyloid-related imaging abnormalities (ARIA) remain a major safety problem for this class of drugs. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Relationship Between Therapeutic Activity and Preferential Targeting of Toxic Soluble Aggregates by Amyloid-Beta-Directed Antibodies

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2024-04-25

Overall, these results suggest that selectivity for soluble toxic Aβ oligomers may be a driver of clinical efficacy, with a potentially reduced risk of ARIA if engagement with plaque is minimized. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2023-11-22

The administration of mAbs that specifically target the N-terminus of Aβ showed promising results in reducing Aβ burden and ameliorating cognitive decline. 5 key findings →

Design: systematic review Participants: 34 Evidence: high

Full summary, score breakdown and related studies → Original source

FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

⚠ Regulatory decision — not a study alzhub usefulness score 15 out of 100. U.S. Food and Drug Administration (announced via Biogen press release) 2023-01-06

The FDA gave lecanemab (Leqembi) accelerated approval based on Phase 2 data showing it reduced amyloid plaque in the brain, ahead of full Phase 3 results. 3 key findings →

Design: regulatory decision Evidence: early

Full summary, score breakdown and related studies → Original source

FDA Approves Treatment for Adults with Alzheimer's Disease (Kisunla / donanemab-azbt)

⚠ Regulatory decision — not a study alzhub usefulness score 15 out of 100. U.S. Food and Drug Administration 2024-07-02

The FDA approved donanemab (Kisunla) as a monthly IV infusion for people with early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed amyloid plaques. 3 key findings →

Design: regulatory decision Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events